PGx-based anti-coagulant therapy with Warfarin Dosing
Not Applicable
Recruiting
- Conditions
- Atrial fibrillation
- Registration Number
- JPRN-UMIN000007642
- Lead Sponsor
- Hyogo University of Health Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who have taken warfarin before. 2) Patients who urgently have to start anti-coagulant therapy. 3) Patients with a history of the prosthetic valve replacement. 4) Patients for whom target INR 2.0-3.0 are inadequate. 5) Patients with a severe hepatic or renal disorder. 6) Patients with thyroid dysfunction. 7) Patients who are applicable to contraindication to warfarin therapy. 8) Patients who take medicines that interact with warfarin. 9) Patients who cannot understand or practice the dietary instruction. 10) Patients judged by investigators as ineligible for study enrollment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Duration required for determination of stable maintenance dose. (The number of visits to the hospital and the changes in dose from initial to final dose until reaching the target INR (1.8 to 3.0) for the second time in a row.)
- Secondary Outcome Measures
Name Time Method 1)The bleeding events or thromboembolic events. 2)Any other adverse clinical events. 3)The number of adjustment of warfarin dose.